Mellor R, Lancaster K, Ritter A. Recovery from alcohol problems in the absence of treatment: a qualitative narrative analysis. Addiction. 2021 Jun;116(6):1413-23. doi: 10.1111/add.15288
Garbutt JC, Greenblatt AM, West SL, Morgan LC, Kampov-Polevoy A, Jordan HS, Bobashev GV. Clinical and biological moderators of response to naltrexone in alcohol dependence: a systematic review of the evidence. Addiction. 2014 Aug;109(8):1274-84. doi: 10.1111/add.12557
Martin-Richard M, Gallego R, Pericay C, Garcia Foncillas JG, Queralt B, Casado E, Barriuso J, Iranzo V, Juez I, Visa L, Saigi E, Barnadas A, Garcia-Albeniz X, Maurel J. Multicenter phase II study of oxaliplatin and sorafenib in advanced gastric adenocarcinoma after failure of cisplatin and fluoropyrimidine treatment. A GEMCAD study. Invest New Drugs. 2013 Dec;31(6):1573-9.
Brown TM, Horblyuk RV, Grotzinger KM, Matzdorff AC, Pashos CL. Patient-reported treatment burden of chronic immune thrombocytopenia therapies. BMC Blood Disord. 2012 Mar 1;12(1):2.
West R, Gilsenan A, Coste F, Zhou X, Brouard R, Nonnemaker J, Curry SJ, Sullivan SD. The ATTEMPT cohort: a multi-national longitudinal study of predictors, patterns and consequences of smoking cessation; introduction and evaluation of internet recruitment and data collection methods. Addiction. 2006 Sep 1;101(9):1352-61.
Estrada CA, Unterborn JN, Price J, Thompson D, Gibson L. Judging the effectiveness of clinical pathways for pneumonia: the role of risk adjustment. Eff Clin Pract. 2000 Sep 1;3(5):221-8.